Mixed-Carrier Pneumococcal Conjugate Composition for Broader Serotype Immunity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing pneumococcal vaccines are ineffective in infants and elderly subjects due to their underdeveloped or impaired immune systems, and current mixed carrier approaches have technical issues and reduced responses when administered with acellular pertussis vaccines.
Innovation Solution
A 21-valent pneumococcal conjugate composition using a mixed carrier system with CRM197 and tetanus toxoid, conjugating 21 different pneumococcal capsular polysaccharides to enhance immune response, including serotypes not covered by existing vaccines, such as 9N, 8, 10A, 11A, 12F, 15B, 22F, and 33F, with improved antibody responses.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of manufacture
If capsular polysaccharides are conjugated to a single protein carrier (single carrier approach), then the vaccine structure is simpler and manufacturing is easier, but the immune response is insufficient in infants and elderly subjects
Solution Approach 1:
The patent divides the single carrier system into multiple carrier proteins (CRM197, tetanus toxoid, and diphtheria toxoid), each conjugated to specific pneumococcal serotypes. This segmentation allows optimization of immune response for different serotypes while maintaining manageable manufacturing complexity through standardized conjugation protocols.
Solution Approach 2:
The patent creates a composite vaccine system combining multiple protein carriers (CRM197, tetanus toxoid, diphtheria toxoid) with corresponding pneumococcal polysaccharides. This composite approach leverages the immunogenic properties of different carriers to enhance overall vaccine effectiveness in infants and elderly subjects.
2Adaptability or versatility
If more pneumococcal serotypes are included in the vaccine, then the coverage is broader, but the immune response to individual serotypes may be diluted
Solution Approach 1:
The patent assigns different carrier proteins to specific serotype groups based on their immunogenic properties. For example, certain serotypes are conjugated to CRM197 while others use tetanus toxoid or diphtheria toxoid. This local optimization ensures each serotype receives the most effective carrier match, maintaining strong immune responses across all 13 serotypes.
Solution Approach 2:
The patent varies the carrier protein type as a parameter for different serotypes rather than using a uniform approach. This parameter change allows tailoring the immunogenicity profile to match the specific requirements of each serotype, thereby maintaining robust antibody responses despite expanded coverage.
3Reliability
If mixed carrier approach is used with multiple protein carriers, then the immune response is enhanced, but the vaccine formulation becomes more complex
Solution Approach 1:
The patent employs three different protein carriers (CRM197, tetanus toxoid, diphtheria toxoid) that serve multiple functions: they act as immunogenic carriers, provide T-cell help for polysaccharide-specific B-cell activation, and can be conjugated using standardized chemical protocols. This multi-functionality reduces the practical complexity despite the diversity of carriers.
Solution Approach 2:
The patent uses carrier proteins as intermediaries that bridge the gap between the non-immunogenic pneumococcal polysaccharides and the immune system. These intermediary carriers provide the necessary immunogenic scaffold and T-cell epitopes to elicit strong immune responses against the polysaccharide antigens.
Data Source
AI summary
Provided are mixed carrier, multivalent pneumococcal conjugate compositions comprising 21 different pneumococcal capsular polysaccharide-protein conjugates, wherein each of the conjugates includes a capsular polysaccharide from a different serotype of Streptococcus pneumoniae conjugated to either tetanus toxoid (TT) or CRM197, wherein the Streptococcus pneumoniae serotypes are selected from 1, 3, 4, 5, 6A, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 18C, 19A, 19F, 22F, 23F, and 33F, where the capsular polysaccharides of two of serotypes 1, 3, and 5 and one or both of serotypes 15B and 22F are conjugated to TT and the remaining capsular polysaccharides are conjugated to CRM197. Also provided are methods of producing the mixed carrier, multivalent pneumococcal conjugate compositions and methods of using the same for prophylaxis against Streptococcus pneumoniae infection or disease in a subject.